查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1441959

结核病诊断测试市场-按测试类型（放射线照相、诊断实验室、分子诊断、潜伏感染检测、细胞激素检测分析、抗药性检测、噬菌体分析）、最终用途-全球预测，2024-2032

Tuberculosis Diagnostics Test Market-By Test Type (Radiographic, Diagnostic Laboratory, Molecular Diagnostics, Detection of Latent Infection, Cytokine Detection Assay, Detection of Drug Resistance, Phage Assay), End-use-Global Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 216 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在可用性增加和提高这些诊断的可负担性的努力的推动下，2024 年至 2032 年间，全球结核病诊断测试市场的CAGR将超过 5.5%。由于结核病仍然是全球健康问题，因此迫切需要准确且易于使用的诊断工具。

例如，2023 年9 月，用于结核病(TB) 诊断和利福平抗药性检测的Xpert MTB/RIF 分子检测和利福平抗药性检测的供应商丹纳赫公司宣布将其标准结核病检测盒的价格降至7.97 美元。这标誌着低收入和中等收入国家的价格较当前 9.98 美元下降了 20%，以应对国际社会日益加大的降价 50% 的压力。丹纳赫公司计划以较低的价格向全球基金和符合 Cepheid 全球访问计划资格的欠发达国家提供这些墨盒。

技术和製造流程的创新正在降低成本，使这些测试变得更加经济实惠和容易获得，特别是在资源匮乏的环境中。随着对抗结核病的努力不断加强，对可靠诊断的需求不断增长，以确保疾病的早期发现和有效管理。

整个结核病诊断测试行业根据测试类型、最终用户和地区进行分类。

从2024年到2032年，分子诊断领域将经历重大发展。聚合酶链反应（PCR）和核酸扩增检验（NAAT）等分子检验可以快速且准确地检测结核病和抗药性。它们识别结核菌特定遗传物质的能力彻底改变了诊断，从而实现早期检测和治疗启动。随着医疗保健系统优先考虑高效和精确的诊断，对分子检测的需求持续增长，塑造了全球结核病诊断的模式。

从 2024 年到 2032 年，即时检测领域的结核病诊断测试市场规模将出现显着的CAGR。由于结核病仍然是全球重要的健康问题，因此对快速且易于使用的诊断工具的需求至关重要。 POCT 具有在患者床边或远端环境中快速获得结果的优点，有助于迅速开始治疗并降低传播率。随着医疗保健系统强调早期检测和干预，结核病诊断中对 POCT 解决方案的需求持续增长，推动市场扩张和创新。

亚太地区结核病诊断测试市场从 2024 年到 2032 年将呈现出值得称讚的CAGR。全球结核病病例很大一部分发生在亚太国家，因此迫切需要准确且易于使用的诊断测试。政府和医疗机构正在投资结核病控制项目，从而刺激了对有助于早期发现和治疗的诊断工具的需求。这一趋势凸显了亚太地区在塑造结核病诊断测试市场轨迹的关键作用。

例如，2023年10月，国家结核病消除计画（NTEP）将SerumMylab国内开发的潜伏性结核病检测测试纳入到2025年根除传染病的计画中。这种创新测试被称为Cy-TB，可以在潜伏感染出现之前识别出潜伏感染。进展为活动性疾病。要实现到 2025 年消除结核病的目标，就必须检​​测和治疗潜伏性结核病感染 (LTBI)。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：结核病诊断测试产业见解

  • 产业生态系统分析
  • 技术景观
  • 监管环境
  • 产业影响力
    • 成长动力
      • 全球结核病负担不断增加
      • 结核病诊断技术的进步
      • 提高对结核病的认识和筛检计划
      • 即时检测 (POCT) 激增
    • 产业陷阱与挑战
      • 敏感性和特异性有限
      • 严格的监管场景
  • 成长潜力分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：结核病诊断测试市场规模和预测：按测试类型，2018-2032 年

  • 主要动向：依测试类型
  • 射线照相法
  • 诊断实验室方法
    • 显微镜检查
    • 基于文化的技术
    • 血清学检测
  • 分子诊断
    • 聚合酶炼式反应 (PCR)
    • 核酸扩增检验（NAAT）
    • GeneXpert MTB/RIF
  • 检测潜伏感染
    • 结核菌素皮肤试验（TST）
    • 干扰素-γ释放测定（IGRA）
  • 细胞激素检测分析
  • 抗药性检测（DST）
  • 噬菌体测定
  • 其他测试类型

第 6 章：结核病诊断测试市场规模和预测：按最终用途分类，2018-2032 年

  • 主要动向：依最终用途
  • 病理实验室
  • 即时检测 (POCT)
  • 其他最终用户

第 7 章：结核病诊断测试市场规模与预测：按地区划分，2018-2032 年

  • 主要动向：按地区
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿联酋
    • 中东和非洲其他地区

第 8 章：公司简介

  • Abbott Laboratories
  • Becton, Dickinson and Company (BD)
  • bioMerieux SA
  • Cepheid (Danaher Corporation)
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Hain Lifescience GmbH
  • Oxford Immunotec (PerkinElmer)
  • Qiagen N.V.
  • Roche Molecular Systems Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
简介目录
Product Code: 7892

Global Tuberculosis Diagnostics Test Market will witness over 5.5% CAGR between 2024 and 2032, spurred by increased availability and efforts to enhance the affordability of these diagnostics. With tuberculosis remaining a global health concern, there is a pressing need for accurate and accessible diagnostic tools.

For instance, in September 2023, Danaher Corporation, the provider of the Xpert MTB/RIF molecular test for tuberculosis (TB) diagnosis, and rifampicin resistance detection, declared a reduction in the price of its standard TB test cartridge to $7.97. This marked a 20% decrease from the current $9.98 price in low- and middle-income countries in response to mounting international pressure for a 50% reduction. Danaher Corporation planned to offer the cartridges at a reduced rate to the Global Fund and less-developed countries qualifying for Cepheid's Global Access Programme.

Innovations in technology and manufacturing processes are driving down costs, making these tests more affordable and accessible, particularly in low-resource settings. As efforts to combat tuberculosis intensify, the demand for reliable diagnostics continues to grow, ensuring early detection and effective management of the disease.

The overall Tuberculosis Diagnostics Test Industry is classified based on the test type, end-user, and region.

Molecular diagnostics segment will undergo significant development from 2024 to 2032. Molecular tests, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), offer rapid and accurate detection of tuberculosis and drug resistance. Their ability to identify specific genetic material of the TB bacterium revolutionizes diagnosis, enabling early detection and treatment initiation. As healthcare systems prioritize efficient and precise diagnostics, the demand for molecular tests continues to grow, shaping the landscape of tuberculosis diagnosis worldwide.

Tuberculosis diagnostics test market size from the point-of-care testing segment will register a noteworthy CAGR from 2024 to 2032. With tuberculosis remaining a significant global health concern, the need for rapid and accessible diagnostic tools is paramount. POCT offers the advantage of quick results at the patient's bedside or in remote settings, facilitating prompt treatment initiation and reducing transmission rates. As healthcare systems emphasize early detection and intervention, the demand for POCT solutions in tuberculosis diagnostics continues to grow, driving market expansion and innovation.

Asia Pacific tuberculosis diagnostics test market will showcase a commendable CAGR from 2024 to 2032. With a significant portion of global tuberculosis cases occurring in Asia Pacific countries, there is a pressing demand for accurate and accessible diagnostic tests. Governments and healthcare organizations are investing in tuberculosis control programs, thus fueling the demand for diagnostic tools to aid in early detection and treatment. This trend underscores the pivotal role of the Asia Pacific region in shaping the trajectory of the tuberculosis diagnostics test market.

For instance, in October 2023, The National Tuberculosis Elimination Programme (NTEP) incorporated SerumMylab's domestically developed latent tuberculosis detection test into its initiatives to eradicate the infectious disease by 2025. This innovative test, known as Cy-TB, can identify latent infection before it progresses into an active disease. Meeting the TB elimination target by 2025 necessitates testing and treating latent TB infection (LTBI).

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Base estimates and working
  • 1.3 Forecast calculations
  • 1.4 Data sources
    • 1.4.1 Primary
    • 1.4.2 Secondary
      • 1.4.2.1 Paid sources
      • 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Global tuberculosis diagnostics test market 360 degree synopsis, 2018 - 2032
    • 2.1.1 Regional trends
    • 2.1.2 Test type trends
    • 2.1.3 End-use trends

Chapter 3 Tuberculosis Diagnostics Test Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Technology landscape
  • 3.3 Regulatory landscape
  • 3.4 Industry impact forces
    • 3.4.1 Growth drivers
      • 3.4.1.1 Rising burden of tuberculosis globally
      • 3.4.1.2 Advancement in tuberculosis diagnostics techniques
      • 3.4.1.3 Increasing awareness and screening programs regarding tuberculosis
      • 3.4.1.4 Surge in Point-of-Care testing (POCT)
    • 3.4.2 Industry pitfalls and challenges
      • 3.4.2.1 Limited sensitivity and specificity
      • 3.4.2.2 Stringent regulatory scenario
  • 3.5 Growth potential analysis
    • 3.5.1 By test type
    • 3.5.2 By end-use
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis, 2023
  • 4.3 Competitive analysis of major market players, 2023
  • 4.4 Competitive positioning matrix, 2023
  • 4.5 Strategic outlook matrix, 2023

Chapter 5 Tuberculosis Diagnostics Test Market Size and Forecast, By Test Type, 2018-2032 (USD Million)

  • 5.1 Key trends, by test type
  • 5.2 Radiographic method
  • 5.3 Diagnostic laboratory methods
    • 5.3.1 Microscopy
    • 5.3.2 Culture-based techniques
    • 5.3.3 Serological tests
  • 5.4 Molecular diagnostics
    • 5.4.1 Polymerase chain reaction (PCR)
    • 5.4.2 Nucleic acid amplification tests (NAAT)
    • 5.4.3 GeneXpert MTB/RIF
  • 5.5 Detection of latent infection
    • 5.5.1 Tuberculin skin test (TST)
    • 5.5.2 Interferon-gamma release assays (IGRAs)
  • 5.6 Cytokine detection assay
  • 5.7 Detection of drug resistance (DST)
  • 5.8 Phage assay
  • 5.9 Other test types

Chapter 6 Tuberculosis Diagnostics Test Market Size and Forecast, By End-use, 2018-2032 (USD Million)

  • 6.1 Key trends, by end-use
  • 6.2 Pathological laboratories
  • 6.3 Point of care testing (POCT)
  • 6.4 Other end users

Chapter 7 Tuberculosis Diagnostics Test Market Size and Forecast, By Region, 2018-2032 (USD Million)

  • 7.1 Key trends, by region
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
    • 7.5.4 Rest of Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 South Africa
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

  • 8.1 Abbott Laboratories
  • 8.2 Becton, Dickinson and Company (BD)
  • 8.3 bioMerieux SA
  • 8.4 Cepheid (Danaher Corporation)
  • 8.5 F. Hoffmann-La Roche Ltd.
  • 8.6 Hologic, Inc.
  • 8.7 Hain Lifescience GmbH
  • 8.8 Oxford Immunotec (PerkinElmer)
  • 8.9 Qiagen N.V.
  • 8.10 Roche Molecular Systems Inc.
  • 8.11 Siemens Healthineers AG
  • 8.12 Thermo Fisher Scientific Inc.